[{"id":"f8a566d4-1220-4795-a41e-999d20763d92","acronym":"","url":"https://clinicaltrials.gov/study/NCT05245500","created_at":"2022-02-18T14:52:54.785Z","updated_at":"2024-07-02T16:34:59.606Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion","source_id_and_acronym":"NCT05245500","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" MTAP","pipe":"","alterations":" ","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navlimetostat (BMS‐986504)"],"overall_status":"Recruiting","enrollment":" Enrollment 370","initiation":"Initiation: 06/02/2022","start_date":" 06/02/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2024-06-03"}]